Advertisement

Comparing dosimetry of locally advanced cervical cancer patients treated with 3 versus 4 fractions of MRI-guided brachytherapy

Published:December 16, 2022DOI:https://doi.org/10.1016/j.brachy.2022.11.005

      Abstract

      PURPOSE

      To demonstrate the feasibility of treating cervical cancer patients with MRI-guided brachytherapy (MRgBT) using 24 Gy in 3 fractions (F) versus a standard, more resource-intensive regimen of 28 Gy in 4F, and its ability to meet EMBRACE II planning aims.

      METHODS AND MATERIALS

      A retrospective review of 224 patients with FIGO Stage IB–IVA cervical cancer treated with 28 Gy/4F (n = 91) and 24 Gy/3F (n = 133) MRgBT between 2016-2021 was conducted. Multivariable linear regression models were fitted to compare dosimetric parameters between the two groups, adjusting for CTVHR and T stage.

      RESULTS

      Most patients had squamous cell carcinoma, T2b disease, and were treated with intracavitary applicator plus interstitial needles (96%). The 28 Gy/4F group had higher CTVHR (median 28 vs. 26 cm3, p = 0.04), CTVIR D98% (mean 65.5 vs. 64.5 Gy, p = 0.03), rectum D2cm3 (mean 61.7 vs. 59.2 Gy, p = 0.04) and bladder D2cm3 (81.3 vs. 77.9 Gy, p = 0.03). There were no significant differences in the proportion of patients meeting the EMBRACE II OAR dose constraints and planning aims, except fewer patients treated with 28 Gy/4F met rectum D2cm3 < 65 Gy (73 vs. 85%, p = 0.027) and ICRU rectovaginal point < 65 Gy (65 vs. 84%, p = 0.005).

      CONCLUSIONS

      Cervical cancer patients treated with 24 Gy/3F MRgBT had comparable target doses and lower OAR doses compared to those treated with 28 Gy/4F. A less-resource intense fractionation schedule of 24 Gy/3F is an alternative to 28 Gy/4F in cervix MRgBT.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Brachytherapy
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Lanciano RM
        • Won M
        • Coia LR
        • Hanks GE.
        Pretreatment and treatment factors associated with improved outcome in squamous cell carcinoma of the uterine cervix: a final report of the 1973 and 1978 patterns of care studies.
        Int J Radiat Oncol Biol Phys. 1991; 20 ([Internet][cited April 6, 2022]Available at): 667-676
        • Perez CA
        • Grigsby PW
        • Chao K s.C
        • et al.
        Tumor size, irradiation dose, and long-term outcome of carcinoma of uterine cervix.
        Int J Radiat Oncol Biol Phys. 1998; 41: 307-317
        • Montana GS
        • Martz KL
        • Hanks GE.
        Patterns and sites of failure in cervix cancer treated in the U.S.A. in 1978.
        Int J Radiat Oncol Biol Phys. 1991; 20 ([Internet][cited April 6, 2022]Available at): 87-93
        • Logsdon MD
        • Eifel PJ.
        Figo IIIB squamous cell carcinoma of the cervix: an analysis of prognostic factors emphasizing the balance between external beam and intracavitary radiation therapy.
        Int J Radiat Oncol Biol Phys. 1999; 43 ([Internet][cited April 6, 2022]Available at): 763-775
        • Pötter R
        • Dimopoulos J
        • Georg P
        • et al.
        Clinical impact of MRI assisted dose volume adaptation and dose escalation in brachytherapy of locally advanced cervix cancer.
        Radiother Oncol. 2007; 83: 148-155
        • Dimopoulos JCA
        • Petrow P
        • Tanderup K
        • et al.
        Recommendations from Gynaecological (GYN) GEC-ESTRO Working Group (IV): basic principles and parameters for MR imaging within the frame of image based adaptive cervix cancer brachytherapy.
        Radiother Oncol. 2012; 103 ([Internet][cited April 7, 2022]Available at: /pmc/articles/PMC3336085/): 113
        • Tanderup K
        • Nesvacil N
        • Kirchheiner K
        • et al.
        Evidence-based dose planning aims and dose prescription in image-guided brachytherapy combined with radiochemotherapy in locally advanced cervical cancer.
        Semin Radiat Oncol. 2020; 30 ([Internet][cited April 21, 2022]Available at): 311-327
        • Pötter R
        • Tanderup K
        • Kirisits C
        • et al.
        The EMBRACE II study: the outcome and prospect of two decades of evolution within the GEC-ESTRO GYN working group and the EMBRACE studies.
        Clin Transl Radiat Oncol. 2018; 9 ([Internet][cited April 21, 2022]Available at): 48-60
      1. ICRU Report 89, Prescribing, recording, and reporting brachytherapy for cancer of the cervix – ICRU [Internet]. [cited April 7, 2022]. Available at: https://www.icru.org/report/icru-report-89-prescribing-recording-and-reporting-brachytherapy-for-cancer-of-the-cervix/

        • Pötter R
        • Tanderup K
        • Schmid MP
        • et al.
        MRI-guided adaptive brachytherapy in locally advanced cervical cancer (EMBRACE-I): a multicentre prospective cohort study.
        Lancet Oncol. 2021; 22 ([Internet][cited April 22, 2022]Available at): 538-547
        • Kirisits C
        • Pötter R
        • Lang S
        • et al.
        Dose and volume parameters for MRI-based treatment planning in intracavitary brachytherapy for cervical cancer.
        Int J Radiat Oncol Biol Phys. 2005; 62 ([Internet][cited April 22, 2022]Available at): 901-911
        • Albuquerque K
        • Hrycushko BA
        • Harkenrider MM
        • et al.
        Compendium of fractionation choices for gynecologic HDR brachytherapy-An American Brachytherapy Society Task Group Report.
        Brachytherapy. 2019; 18 ([Internet][cited April 22, 2022]Available at): 429-436
        • Chino J
        • Annunziata CM
        • Beriwal S
        • et al.
        Radiation therapy for cervical cancer: executive summary of an ASTRO clinical practice guideline.
        Pract Radiat Oncol. 2020; 10 ([Internet][cited April 22, 2022]Available at): 220-234
        • Pötter R
        • Georg P
        • Dimopoulos JCA
        • et al.
        Clinical outcome of protocol based image (MRI) guided adaptive brachytherapy combined with 3D conformal radiotherapy with or without chemotherapy in patients with locally advanced cervical cancer.
        Radiother Oncol. 2011; 100 ([Internet][cited April 15, 2022]Available at): 116-123
        • Viswanathan AN
        • Beriwal S
        • De Los Santos JF
        • et al.
        The American Brachytherapy Society Treatment Recommendations for Locally Advanced Carcinoma of the Cervix Part II: High Dose-Rate Brachytherapy.
        Brachytherapy. 2012; 11 ([Internet][cited April 6, 2022]Available at: /pmc/articles/PMC3489267/): 47
        • Nomden CN
        • De Leeuw AAC
        • Roesink JM
        • et al.
        Clinical outcome and dosimetric parameters of chemo-radiation including MRI guided adaptive brachytherapy with tandem-ovoid applicators for cervical cancer patients: a single institution experience.
        Radiother Oncol. 2013; 107 ([Internet][cited April 15, 2022]Available at): 69-74
        • le Guyader M
        • Lam Cham Kee D
        • Thamphya B
        • et al.
        High-dose-rate brachytherapy boost for locally advanced cervical cancer: oncological outcome and toxicity analysis of 4 fractionation schemes.
        Clin Transl Radiat Oncol. 2022; 32: 15-23
        • Pötter R
        • Haie-Meder C
        • Van Limbergen E
        • et al.
        Recommendations from gynaecological (GYN) GEC ESTRO working group (II): concepts and terms in 3D image-based treatment planning in cervix cancer brachytherapy—3D dose volume parameters and aspects of 3D image-based anatomy, radiation physics, radiobiology.
        Radiother Oncol. 2006; 78 ([Internet][cited April 26, 2022]Available at): 67-77
        • Small W
        • Mell LK
        • Anderson P
        • et al.
        Consensus guidelines for the delineation of the clinical target volume for intensity modulated pelvic radiotherapy in the postoperative treatment of endometrial and cervical cancer.
        Int J Radiat Oncol Biol Phys. 2008; 71 ([Internet][cited April 22, 2022]Available at/pmc/articles/PMC2752724/): 428
        • Skliarenko J
        • Carlone M
        • Tanderup K
        • et al.
        Technique adaptation, strategic replanning, and team learning during implementation of MR-guided brachytherapy for cervical cancer.
        Brachytherapy. 2018; 17 ([Internet][cited May 10, 2022]Available at): 86-93
        • Morgia M
        • Cuartero J
        • Walsh L
        • et al.
        Tumor and normal tissue dosimetry changes during MR-guided pulsed-dose-rate (PDR) brachytherapy for cervical cancer.
        Radiother Oncol. 2013; 107 ([Internet][cited November 6, 2022]Available at): 46-51
      2. ICRU Report 89, Prescribing, recording, and reporting brachytherapy for cancer of the cervix – ICRU [Internet]. [cited March 27, 2022]. Available at: https://www.icru.org/report/icru-report-89-prescribing-recording-and-reporting-brachytherapy-for-cancer-of-the-cervix/

        • Fokdal L
        • Sturdza A
        • Mazeron R
        • et al.
        Image guided adaptive brachytherapy with combined intracavitary and interstitial technique improves the therapeutic ratio in locally advanced cervical cancer: analysis from the retroEMBRACE study.
        Radiother Oncol. 2016; 120 ([Internet][cited April 15, 2022]Available at): 434-440
        • Sturdza AE
        • Knoth J.
        Image-guided brachytherapy in cervical cancer including fractionation.
        Int J Gynecol Cancer. 2022; 32 ([Internet][cited April 18, 2022]Available at): 273-280
        • Serban M
        • Kirisits C
        • de Leeuw A
        • et al.
        Ring versus ovoids and intracavitary versus intracavitary-interstitial applicators in cervical cancer brachytherapy: results from the EMBRACE I study.
        Int J Radiat Oncol Biol Phys. 2020; 106 ([Internet][cited May 22, 2022]Available at): 1052-1062
        • Mahantshetty U
        • Krishnatry R
        • Hande V
        • et al.
        Magnetic resonance image guided adaptive brachytherapy in locally advanced cervical cancer: an experience from a tertiary cancer center in a low and middle income countries setting.
        Int J Radiat Oncol Biol Phys. 2017; 99 ([Internet][cited April 15, 2022]Available at): 608-617
        • Tanderup K
        • Fokdal LU
        • Sturdza A
        • et al.
        Effect of tumor dose, volume and overall treatment time on local control after radiochemotherapy including MRI guided brachytherapy of locally advanced cervical cancer.
        Radiother Oncol. 2016; 120 ([Internet][cited April 15, 2022]Available at): 441-446
        • Sturdza A
        • Pötter R
        • Fokdal LU
        • et al.
        Image guided brachytherapy in locally advanced cervical cancer: improved pelvic control and survival in RetroEMBRACE, a multicenter cohort study.
        Radiother Oncol. 2016; 120 ([Internet][cited April 15, 2022]Available at): 428-433
        • Mazeron R
        • Castelnau-Marchand P
        • Escande A
        • et al.
        Tumor dose-volume response in image-guided adaptive brachytherapy for cervical cancer: a meta-regression analysis.
        Brachytherapy. 2016; 15 ([Internet][cited April 19, 2022]Available at): 537-542
        • Horne ZD
        • Karukonda P
        • Kalash R
        • et al.
        Single-institution experience in 3D MRI-based brachytherapy for cervical cancer for 239 women: can dose overcome poor response?.
        Int J Radiat Oncol Biol Phys. 2019; 104 ([Internet][cited April 15, 2022]Available at): 157-164
        • Mazeron R
        • Fokdal LU
        • Kirchheiner K
        • et al.
        Dose–volume effect relationships for late rectal morbidity in patients treated with chemoradiation and MRI-guided adaptive brachytherapy for locally advanced cervical cancer: results from the prospective multicenter EMBRACE study.
        Radiother Oncol. 2016; 120: 412-419
        • Spampinato S
        • Fokdal LU
        • Pötter R
        • et al.
        Risk factors and dose-effects for bladder fistula, bleeding and cystitis after radiotherapy with imaged-guided adaptive brachytherapy for cervical cancer: an EMBRACE analysis.
        Radiother Oncol. 2021; 158 ([Internet][cited April 15, 2022]Available at): 312-320
        • Pötter R
        • Tanderup K
        • Schmid MP
        • et al.
        MRI-guided adaptive brachytherapy in locally advanced cervical cancer (EMBRACE-I): a multicentre prospective cohort study.
        Lancet Oncol. 2021; 22 ([Internet][cited April 17, 2022]Available at): 538-547
        • Tanderup K
        • Nesvacil N
        • Kirchheiner K
        • et al.
        Evidence-based dose planning aims and dose prescription in image-guided brachytherapy combined with radiochemotherapy in locally advanced cervical cancer.
        Semin Radiat Oncol. 2020; 30 ([Internet][cited April 19, 2022]Available at): 311-327
        • Georg P
        • Pötter R
        • Georg D
        • et al.
        Dose effect relationship for late side effects of the rectum and urinary bladder in magnetic resonance image-guided adaptive cervix cancer brachytherapy.
        Int J Radiat Oncol Biol Phys. 2012; 82 ([Internet][cited April 16, 2022]Available at): 653-657
        • Mazeron R
        • Maroun P
        • Castelnau-Marchand P
        • et al.
        Pulsed-dose rate image-guided adaptive brachytherapy in cervical cancer: dose-volume effect relationships for the rectum and bladder.
        Radiother Oncol. 2015; 116 ([Internet][cited April 16, 2022]Available at): 226-232
        • Tanderup K
        • Lindegaard JC
        • Kirisits C
        • et al.
        Image guided adaptive brachytherapy in cervix cancer: a new paradigm changing clinical practice and outcome.
        Radiother Oncol. 2016; 120 ([Internet][cited April 21, 2022]Available at): 365-369
        • Kirchheiner K
        • Nout RA
        • Lindegaard JC
        • et al.
        Dose-effect relationship and risk factors for vaginal stenosis after definitive radio(chemo)therapy with image-guided brachytherapy for locally advanced cervical cancer in the EMBRACE study.
        Radiother Oncol. 2016; 118 ([Internet][cited April 21, 2022]Available at): 160-166
        • Mahantshetty U
        • Gurram L
        • Bushra S
        • et al.
        Single application multifractionated image guided adaptive high-dose-rate brachytherapy for cervical cancer: dosimetric and clinical outcomes.
        Int J Radiat Oncol Biol Phys. 2021; 111 ([Internet][cited April 18, 2022]Available at): 826-834
        • Rao BS
        • Das P
        • Subramanian BV
        • et al.
        A comparative analysis of two different dose fractionation regimens of high dose rate intracavitary brachytherapy in treatment of carcinoma of uterine cervix: a prospective randomized study.
        J Clin Diagn Res. 2017; 11 ([Internet][cited April 24, 2022]Available at): XC06-XC10
        • Damast S
        • Tien CJ
        • Young M
        • et al.
        Single application hybrid interstitial brachytherapy for cervical cancer: an institutional approach during the COVID-19 pandemic.
        J Contemp Brachytherapy. 2022; 14 ([Internet][cited April 18, 2022]Available at: /pmc/articles/PMC8867238/): 66
        • Souhami L
        • Corns R
        • Duclos M
        • et al.
        Long-term results of high-dose rate brachytherapy in cervix cancer using a small number of fractions.
        Gynecol Oncol. 2005; 97 ([Internet][cited April 24, 2022]Available at): 508-513
        • Berger T
        • Seppenwoolde Y
        • Pötter R
        • et al.
        Importance of technique, target selection, contouring, dose prescription, and dose-planning in external beam radiation therapy for cervical cancer: evolution of practice from EMBRACE-I to II.
        Int J Radiat Oncol Biol Phys. 2019; 104 ([Internet][cited April 18, 2022]Available at): 885-894
        • Kirchheiner K
        • Czajka-Pepl A
        • Ponocny-Seliger E
        • et al.
        Posttraumatic stress disorder after high-dose-rate brachytherapy for cervical cancer with 2 fractions in 1 application under spinal/epidural anesthesia: incidence and risk factors.
        Int J Radiat Oncol Biol Phys. 2014; 89 ([Internet][cited May 10, 2022]Available at): 260-267